Immuneering (IMRX) Operating Leases (2020 - 2026)

Immuneering's Operating Leases history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 18.75% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 18.75% decrease from a year earlier, with the FY2025 full-year figure at $3.4 million, down 10.38% from the prior year.
• Operating Leases retreated to $3.3 million in Q1 2026 per IMRX's latest filing, from $3.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.7 million in Q1 2023 and bottomed at $3.3 million in Q1 2026.
• The 5-year median for Operating Leases is $4.2 million (2023), against an average of $4.2 million.
• Across the five-year window, Operating Leases soared 842.53% in 2022 and slipped 18.75% in 2026, its largest moves.
• Year by year, Operating Leases stood at $4.5 million in 2022, then retreated by 6.72% to $4.2 million in 2023, then declined by 8.13% to $3.8 million in 2024, then fell by 10.38% to $3.4 million in 2025, then declined by 3.21% to $3.3 million in 2026.
• Per Business Quant, the three latest IMRX Operating Leases figures stand at $3.3 million (Q1 2026), $3.4 million (Q4 2025), and $3.9 million (Q3 2025).